Sanofi secured approval from the United States health regulator on Wednesday afternoon for its oral drug Infilbray to treat a rare neurological disorder. The milestone introduces the first approved therapy for type 3 Gaucher disease, a genetic condition causing fatty substances to accumulate in organs. The rollout helps the drugmaker diversify its revenue base as blockbuster asthma treatment Dupixent approaches patent expiration in the early 2030s.

Expanding Beyond Dupixent